isashi Shinkai described the discovery of elvitegravir, a new HIV-1 integrase inhibitor by using a 4-quinolone-3-carboxylic acid scaffold. The oncedaily single tablet of a combination of elvitegravir with a CYP3A4 inhibitor
and a nucleoside reverse transcriptase inhibitor afforded potent and durable
antiretroviral efficacy
